Tirzepatide roughly doubles Ozempic's blood sugar and weight targets in real-world diabetes data
Real-world English records presented at EASD 2026 show tirzepatide helped about twice as many adults with type 2 diabetes hit HbA1c and weight goals as semaglutide.
Summary
Type 2 diabetes shortens healthy lifespan, so how well treatments work in everyday practice matters. Real-world data presented at the 2026 European Association for the Study of Diabetes meeting compared three drugs in English adults with type 2 diabetes: tirzepatide (Mounjaro), injectable semaglutide (Ozempic) and oral semaglutide (Rybelsus). After 12 months, 46.3% of tirzepatide users reached an HbA1c below 6.5%, versus 20.6% on injectable semaglutide and 23.8% on the pill. Weight loss of at least 15% occurred in 24.1% of tirzepatide users, 9.1% on injectable semaglutide and 8.4% on oral semaglutide. The study was retrospective and used propensity-score matching, so it can't fully rule out differences between patients. The write-up, from market analyst GlobalData, gives no patient numbers, side effects, cost or adherence data. The results are promising but not definitive.
Detailed Summary
Type 2 diabetes and excess body weight both erode healthy years, so treatments that improve blood sugar and weight together could matter over decades. A new real-world analysis presented at the 2026 European Association for the Study of Diabetes meeting suggests tirzepatide may do this better than semaglutide.
Researchers reviewed primary-care records in England for adults with type 2 diabetes who had newly started tirzepatide (Mounjaro), injectable semaglutide (Ozempic) or oral semaglutide (Rybelsus). They tracked two goals across 12 months: an HbA1c below 6.5%, a blood test reflecting average glucose over recent months, and body weight loss of at least 15%.
Tirzepatide led on both measures. An HbA1c under 6.5% was reached by 46.3% of tirzepatide patients, compared with 20.6% on injectable semaglutide and 23.8% on the oral form, roughly double. Weight loss of 15% or more occurred in 24.1% of tirzepatide patients, 9.1% on injectable semaglutide and 8.4% on the pill. Tirzepatide is a dual GIP/GLP-1 receptor agonist, while semaglutide targets only GLP-1, and the analyst suggests this dual action may explain the edge, though the data do not prove it.
For readers, the findings reinforce that weight and glycemic control are both meaningful treatment targets, and that drug choice may affect how likely a person is to reach them. Anyone considering these medications should discuss options with a clinician, taking account of tolerability, cost, access and personal health goals.
Several caveats apply. The study was retrospective, not randomized. Propensity-score matching reduces bias but cannot remove it, because prescribers choose drugs for reasons not captured in records. The report, written by an industry analyst, lacks patient numbers, researcher names, persistence rates, side effects and cost data. One year is also short compared with the decades over which diabetes shapes healthspan. Peer-reviewed data and long-term outcome trials are needed to confirm whether these advantages translate into fewer complications and longer healthy life.
Key Findings
- 46.3% of tirzepatide users reached HbA1c below 6.5% at 12 months, versus 20.6% on Ozempic and 23.8% on Rybelsus.
- 24.1% of tirzepatide patients lost at least 15% of body weight, compared with 9.1% on injectable and 8.4% on oral semaglutide.
- The data come from retrospective English primary-care records using propensity-score matching, not a randomized trial.
- Tirzepatide's dual GIP/GLP-1 action may explain its edge, but the report does not prove the mechanism.
- The summary omits patient numbers, adherence, side effects and cost, so real-world advantages remain provisional.
Methodology
This is a news report of a conference presentation (EASD 2026), summarized from a GlobalData analyst write-up. The underlying study is a retrospective propensity-score-matched analysis of English primary-care records. The secondary source is industry-oriented and omits sample size and investigator details.
Study Limitations
Observational data cannot establish causation, and residual confounding persists despite matching. The report gives no sample sizes, persistence rates, safety or cost data, and covers only 12 months. Check the original EASD abstract or a peer-reviewed publication for the full methods and results.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: